Bianca Maria Marin
Mayo Clinic
LuciferaseDrug resistanceCancerInternal medicineRadiologySurgeryOncologyClinical study designEfficacyDiffusion MRIHeterozygote advantageBioluminescence imagingRetrospective cohort studyChemistryTissue microarrayPenetranceIn vivoLatin hypercube samplingSensitivity (control systems)Middle cerebral arteryBiopsyGlioblastomaAntibody-drug conjugateInfarctionBevacizumabChemotherapy regimenBlood–brain barrierMetastasisBrain tumorEpidermal growth factor receptorDrug deliveryDrugAngiogenesisLesionTargeted therapyLuciferinMolecular ResponseDepatuxizumab mafodotinSerial imagingDrug responseTumor growthMedical imagingPhases of clinical researchNonlinear regressionCancer researchRadiation therapyStrokeClinical trialVoxelMonoclonal antibodyExperimental dataDrug developmentPhosphoproteomicsRegulatorComputational biologyEffective diffusion coefficientMedicineEndocytic cycleDistribution (pharmacology)
8Publications
1H-index
2Citations
Publications 9
Newest
#1Begoña Giménez-Cassina López (Brigham and Women's Hospital)H-Index: 11
#2Ishwar N. Kohale (MIT: Massachusetts Institute of Technology)H-Index: 2
Last. Michael S. Regan (Brigham and Women's Hospital)H-Index: 7
view all 28 authors...
Background null Response to targeted therapy varies between patients for largely unknown reasons. Here, we developed and applied an integrative platform using mass spectrometry imaging (MSI), phosphoproteomics, and multiplexed tissue imaging for mapping drug distribution, target engagement, and adaptive response to gain insights into heterogeneous response to therapy. null Methods null Patient derived xenograft (PDX) lines of glioblastoma were treated with adavosertib, a Wee-1 inhibitor, and tis...
Source
#1Bianca Maria Marin (Mayo Clinic)H-Index: 1
#2Kendra A Porath (Mayo Clinic)
Last. Jann N. Sarkaria (Mayo Clinic)H-Index: 67
view all 30 authors...
BACKGROUND Antibody drug conjugates (ADCs) targeting the epidermal growth factor receptor (EGFR), such as depatuxizumab mafodotin (Depatux-M), is a promising therapeutic strategy for glioblastoma (GBM) but recent clinical trials did not demonstrate a survival benefit. Understanding the mechanisms of failure for this promising strategy is critically important. METHODS PDX models were employed to study efficacy of systemic vs intracranial delivery of Depatux-M. Immunofluorescence and MALDI-MSI wer...
Source
#1Susan Christine Massey (Mayo Clinic)H-Index: 8
#2Javier Urcuyo (Mayo Clinic)H-Index: 1
Last. Kristin R. Swanson (ASU: Arizona State University)H-Index: 47
view all 5 authors...
Many drugs investigated for the treatment of glioblastoma (GBM) have had disappointing clinical trial results. Efficacy of these agents is dependent on adequate delivery to sensitive tumor cell populations, which is limited by the blood-brain barrier (BBB). Additionally, tumor heterogeneity can lead to subpopulations of cells with different sensitivities to anti-cancer drugs, further impacting therapeutic efficacy. Thus, it may be important to evaluate the extent to which BBB limitations and het...
Source
#1Javier Urcuyo (Mayo Clinic)H-Index: 1
#2Susan Christine Massey (Mayo Clinic)H-Index: 8
Last. Kristin R. Swanson (Mayo Clinic)H-Index: 47
view all 5 authors...
Source
#1Susan Christine Massey (Mayo Clinic)H-Index: 8
#2Javier UrcuyoH-Index: 1
Last. Kristin R. Swanson (ASU: Arizona State University)H-Index: 47
view all 5 authors...
Many drugs investigated for the treatment of glioblastoma (GBM) have had poor clinical outcomes, as their efficacy is dependent on adequate delivery to sensitive tumor cell populations, which is limited by the blood-brain barrier (BBB). Further complicating evaluation of therapeutic efficacy, tumors can become resistant to anti-cancer drugs, and it can be difficult to gauge the extent to which BBB limitations and resistance each contribute to a drug9s failure. To address this question, we develo...
2 CitationsSource
#1Susan Christine Massey (Mayo Clinic)H-Index: 8
#2Javier Urcuyo (Mayo Clinic)H-Index: 1
Last. Kristin R. Swanson (Mayo Clinic)H-Index: 47
view all 5 authors...
Poor clinical trial outcomes for glioblastoma (GBM) can be attributed to multiple possible causes. GBM is heterogeneous, such that there is a chance of treatment-resistant cells coming to predominate the tumor, and due to the blood brain barrier (BBB) it is also possible that therapy was inadequately delivered to the tumor. Mathematically modeling the dynamics of therapeutic response in patient-derived xenografts (PDX) and fitting the mathematical model to bioluminescence imaging flux data, we m...
Source
#1Gaelle Muller-Greven (Cleveland Clinic)H-Index: 4
#2Bianca Maria Marin (Mayo Clinic)H-Index: 1
Last. Candece L. Gladson (Cleveland Clinic)H-Index: 47
view all 8 authors...
Source
Background: Bioluminescence imaging (BLI) of firefly luciferase expressing cells is widely used for analysis of growth, metastasis and drug response in tumor xenografts. D-luciferin, a commonly used luciferase substrate, has limited brain distribution that may undermine BLI for intracranial xenografts. The synthetic luciferin cyclic alkylamino-luciferin (CycLuc1) is a purported brain penetrant luciferase substrate not yet tested in intracranial xenografts. We compared BLI with CycLuc1 and D-luci...
Source
#1Abhijith Annasamudram (NU: Northwestern University)
#2David Esterquest (Illinois Wesleyan University)
Last. Shyam Prabhakaran (NU: Northwestern University)H-Index: 38
view all 7 authors...
Background and purpose: Chronic lesion locations are associated with neurologic outcomes. However, voxel-based acute infarct maps have not been used to predict long-term deficits and outcomes. The combination of ischemic lesion volume and location may aid in acute outcome prediction models. We evaluated the feasibility of voxel-based lesion mapping in acute ischemic stroke patients. Methods: In a retrospective study of patients with suspected middle cerebral artery (MCA) territory strokes, we id...